Media Coverage

Dechra launches poultry disease treatment

May 23, 2017 - Animal Pharm

By Malcolm Flanagan
Animal Pharm
May 23, 2017 

UK animal health company Dechra Pharmaceuticals has launched a new product for the treatment of one of the poultry industry's most common bacterial diseases among broiler chickens.

The Northwich, Cheshire-headquartered company said Phenocillin has been created for the treatment of necrotic enteritis caused by Clostridium perfringens. Its active ingredient is phenoxymethylpenicillin. The treatment is sold as a 800mg/g powder for use in drinking water. The product will be available in the UK and Europe.

Necrotic enteritis can be treated with a variety of therapeutic antibiotics. Traditionally, the poultry sector's first choice treatments are narrow spectrum antibiotics such as phenoxymethylpenicillin. Phenocillin is lactose-free with high solubility "making it ideal for concentrated stock solutions and convenient for modern poultry farming". Dechra said there is a zero withdrawal time so egg production is unaffected.

The treatment is the latest addition to the Dechra's SoluStab antibiotic range for livestock which also includes Soludox, Soludox, Octacillin, Solamocta, Solacyl, and Metaxol. The respiratory aid for chicken and swine Metaxol was launched by the company in early May.

Dechra brand manager Emma Jennings said: “Necrotic enteritis is the most common bacterial disease in modern broiler flocks and can be financially devastating for farmers. The high concentration of Phenocillin means easy dosage and handling with less waste and the lactose free formula reduces the risk of biofilm development resulting in a high quality and effective product, supporting the responsible use of antimicrobials.

"Phenocillin is a highly effective treatment and we anticipate it will become the preferred solution for veterinary professionals and end users to treat a disease that can very suddenly devastate broiler flocks."

In February this year, Evonik launched a gut probiotic GutCare PY1 on the US feed additive market. It also indicated to inhibit necrotic enteritis outbreak isolates. In November 2016, Elanco gained US marketing authorization for Inteprity and Coban (avilamycin and monensin), an in-feed antimicrobial for broiler chickens.

The product is a combination of two antimicrobials already approved in the US. It indicated for the prevention of mortality caused by necrotic enteritis associated with Clostridium perfringens.

Reprinted with permission of Animal Pharm News




News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum